LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

Search

Biogen Inc

Suletud

Sektor Tervishoid

226.19 0.31

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

222.23

Max

227.03

Põhinäitajad

By Trading Economics

Sissetulek

144M

393M

Müük

-96M

2.3B

P/E

Sektori keskmine

27.06

79.786

Aktsiakasum

3.67

Kasumimarginaal

17.179

Töötajad

7,570

EBITDA

29M

682M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+26.26 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. aug 2024

Turustatistika

By TradingEconomics

Turukapital

-916M

32B

Eelmine avamishind

225.88

Eelmine sulgemishind

226.19

Uudiste sentiment

By Acuity

73%

27%

319 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Biogen Inc Graafik

Seotud uudised

7. aug 2023, 12:03 UTC

Suurimad hinnamuutused turgudel

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback

29. mai 2024, 15:56 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4. okt 2023, 17:55 UTC

Omandamised, ülevõtmised, äriostud

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

1. sept 2023, 15:23 UTC

Omandamised, ülevõtmised, äriostud

Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen -- IBD

25. juuli 2023, 20:03 UTC

Tulu

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25. juuli 2023, 15:41 UTC

Peamised uudised

A Surprising Beneficiary of New Alzheimer's Drugs: GE HealthCare -- Heard on the Street -- WSJ

25. juuli 2023, 14:21 UTC

Tulu

Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25. juuli 2023, 13:25 UTC

Tulu

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

25. juuli 2023, 13:02 UTC

Tulu

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

26.26% tõus

12 kuu keskmine prognoos

Keskmine 284.4 USD  26.26%

Kõrge 342 USD

Madal 200 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

24 ratings

19

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

221.21 / 228.07Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

319 / 369 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.